| (Values in U.S. Thousands) | Dec, 2023 | Sep, 2023 | Jun, 2023 | Mar, 2023 | Dec, 2022 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -3,090 | -3,730 | -4,300 | -2,560 | -3,180 |
| Net Income Growth | +17.16% | +13.26% | -67.97% | +19.50% | +31.76% |
Antibe Therapeutics Inc (ATBPF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Antibe Therapeutics Inc. is a biotech company with a drug platform of therapeutics in pain and inflammation. Its lead drug candidate consists of ATB-346, non-addictive drug for chronic pain and inflammation; ATB-352, for a non-addictive analgesic for treating severe acute pain, while ATB-340 is a GI-safe derivative of aspirin. Antibe Therapeutics Inc. is based in Toronto, Canada.
Fiscal Year End Date: 03/31